Top Industry Leaders in the Bulimia Nervosa Market
Latest Bulimia Nervosa Companies Updates
King's College London (UK): Launched the largest ever study on eating disorders, including bulimia nervosa, in January 2024. This research aims to unlock insights into the causes and personalize treatment approaches.
National Institute of Mental Health (NIMH): Funded research in October 2023 exploring the use of digital therapeutics, like mobile apps and AI-powered interventions, for bulimia nervosa.
Eating Recovery Center (US): Announced progress in developing a Virtual Reality (VR) therapy program specifically for bulimia nervosa, aiming to provide immersive exposure therapy and coping skills training.
National Eating Disorders Association (NEDA): Launched a campaign in September 2023 titled "Break the Cycle: Bulimia Nervosa Awareness Week," promoting early identification and access to treatment.
Beats (UK): Partnered with mental health experts in October 2023 to develop resources and support systems for individuals struggling with eating disorders, including bulimia nervosa, accessible through their streaming platform.Headspace (US): Introduced new guided meditations and mindfulness exercises specifically targeting bulimia nervosa symptoms and urges, accessible within their app.
List of Bulimia Nervosa Key companies in the market:
- Allergan, Inc. (Ireland)
- Eli Lilly and Company (US)
- AstraZeneca (UK)
- Bristol-Myers Squibb Company (US)
- GlaxoSmithKline plc (UK)
- Pfizer Inc. (US)
- Johnson & Johnson Services, Inc. (US)
- Dr. Reddy’s Laboratories Limited (India)
- Lupin Pharmaceuticals, Inc. (India)
- Aurobindo Pharma (India)
- Zydus Cadila (India)
- Apotex Inc. (Canada)
- Teva Pharmaceutical Industries Ltd (Israel)